Seeing Through LEMS: From Early Detection to Advanced Management (CME Webcast)
Activity Description and Purpose
This educational activity for neuro-ophthalmologists focuses on Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting the neuromuscular junction, leading to muscle weakness, fatigue, and autonomic dysfunction. The program aims to enhance the understanding of LEMS among ophthalmologists, covering its pathophysiology, diagnostic criteria, and treatment options. Participants will learn to identify clinical features, implement appropriate diagnostic measures, and evaluate clinical trial data on treatments through interactive case studies and expert discussions. By the end of the activity, ophthalmologists will be better equipped to recognize LEMS, facilitate early diagnosis, and formulate and implement optimal treatment plans for this complex disorder.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify the appropriate diagnostic measures for Lambert-Eaton myasthenic syndrome
- Evaluate clinical trial data on treatment for Lambert-Eaton myasthenic syndrome
- Implement optimal therapeutic strategies for patients with Lambert-Eaton myasthenic syndrome
Faculty
Andrew G. Lee, MD
| |
John J. Chen, MD, PhD Professor of Ophthalmology and Neurology | |
T. Aaron Judd, OD Board-Certified Optometrist Quigley Eye Specialists Fort Myers, Florida
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
John J. Chen, MD, PhD, is a consultant for Amgen Inc and UCB SA.
T. Aaron Judd, OD, has no relevant commercial relationships to disclose.
Andrew G. Lee, MD, is a consultant for AstraZeneca and Bristol-Myers Squibb Company; is an advisory board member of Stoke Therapeutics and Viridian Therapeutics, Inc; and is on the speakers bureau for Alexion Pharmaceuticals, Inc and Amgen Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Robert M. Geist IV, MD, has no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Catalyst Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the MedEdicus LLC or Catalyst Pharmaceuticals, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 325
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation